Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Bitget Daily Contract Market Dynamics

Bitget Daily Contract Market Dynamics

Bitget2024/08/20 06:05
Bitcoin reclaimed the $60,000 level, leading to $20 million in short liquidations and pushing the 4-hour long/short ratio close to 1.2.
 
Bitcoin Contracts Update
- Total Bitcoin Open Interest: $30.9 billion (+3.69%)
- Bitcoin 24-Hour Trading Volume: $52.08 billion (+29.89%)
- Bitcoin 24-Hour Liquidations: $7.38 million (longs) / $21.81 million (shorts)
- Long/Short Ratio: 50.75% / 49.25%
- Funding Rate: -0.0014%
 
Ethereum Contracts Update
- Total Ethereum Open Interest: $10.68 billion (+1.19%)
- Ethereum 24-Hour Trading Volume: $20.98 billion (+28.68%)
- Ethereum 24-Hour Liquidations: $16.57 million (longs) / $8.48 million (shorts)
- Long/Short Ratio: 49.52% / 50.46%
- Funding Rate: 0.0013%
 
Top 3 Open Interest Growth
- NMR: $22.37 million (+580.15%)
- ARPA: $19.87 million (+381.80%)
- COS: $9.1877 million (+131.96%)
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

On Monday, storage chip concept stocks generally rose, with SanDisk (SNDK.US) up by 6%.

智通财经2026/08/17 13:51
U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds

On August 17, AstraZeneca (AZN.US) and Daiichi Sankyo jointly announced that the Phase III DESTINY-Lung04 study of Enhertu (trastuzumab deruxtecan) as a monotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has achieved highly positive results.

智通财经2026/08/17 12:56
AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds